TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10778867
Drug: Intralipid 20%
Normalized name: Intralipid 20% Fat Emulsion for Injection
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid 20% with heparin (0.4 U/kg body weight/min)
Study: 10778867
Drug: Control infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control infusion of saline (150 mmol/L)
Study: 2871784
Drug: Bevantolol 100
Normalized name: bevantolol
DrugBank: Bevantolol (DB01295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevantolol 100 to 400 mg/day
Study: 29231498
Drug: Abdominal acupuncture
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal acupuncture therapy applied to Zhongwan (CV 12), Xiawan (CV 10), Qihai (CV 6), Guanyuan (CV 4), Tianshu (ST 25) and Shuidao (ST 28), once a day, 5 times a week for 3 months
Study: 23461703
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT) and Supportive Listening
Study: 18074229
Drug: Pearl barley
Normalized name: Pearl barley
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pearl barley with high beta-glucan content (7.0 g beta-glucan per day)
Study: 16478760
Drug: Monophasic oral
Normalized name: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic oral contraceptives with 20, 30 or 50 microg/day estrogen
Study: 8295082
Drug: Minimal‐treatment control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal‐treatment control
Study: 31777325
Drug: Chronic Opioid
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic Opioid Therapy (COT) tapering trial
Study: 2453895
Drug: Buprenorphine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.2 mg)
Study: 20651023
Drug: Cysteine plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteine plasma levels after 6 months of CPAP therapy
Study: 17846331
Drug: TP10 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP10 (5 mg/kg dose as a 30-minute intravenous infusion before surgery)
Study: 17846331
Drug: Placebo (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (as a 30-minute intravenous infusion before surgery)
Study: 12541863
Drug: Local group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local group (local injected with IL‐2 + radiotherapy + chemotherapy)
Study: 12541863
Drug: General group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: General group (ivdrip with IL‐2 + radiotherapy + chemotherapy)
Study: 12541863
Drug: Convention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convention group (radiotherapy + chemotherapy)
Study: 9555769
Drug: Early intravenous
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intravenous beta-blocker administration
Study: 9555769
Drug: Oral beta-blocker
Normalized name: beta carotene Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beta-blocker therapy
Study: 9555769
Drug: Nitrates and
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrates and lisinopril treatment
Study: 2499700
Drug: DPT -
Normalized name: Diphtheria, Pertussis, Tetanus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPT - IPV (combined DPT - enhanced injectable polio vaccine)
Study: 2499700
Drug: DPT (Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPT (Conventional Schedule with 3 doses of oral polio vaccine and 2 doses of DPT)
Study: 2499700
Drug: DPT -
Normalized name: Diphtheria, Pertussis, Tetanus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPT - IPV or DPT vaccine alone
Study: 28719572
Drug: Constraint-Induced Aphasia
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-Induced Aphasia Therapy (CIAT)
Study: 22126550
Drug: Taxotere plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxotere plus poldine intravenous chemotherapy (A1)
Study: 22126550
Drug: Taxotere intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxotere intravenous chemotherapy combined with poldine intraperitoneal chemotherapy (A2)
Study: 22126550
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus poldine intravenous chemotherapy (B1)
Study: 22126550
Drug: Paclitaxel intravenous
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel intravenous chemotherapy combined with poldine intraperitoneal chemotherapy (B2)
Study: 11465092
Drug: Intermittent IL-2
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent IL-2 therapy
Study: 10700435
Drug: Arthrocentesis (synovial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrocentesis (synovial fluid aspiration) before injecting 20 mg triamcinolone hexacetonide
Study: 10700435
Drug: No arthrocentesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: No arthrocentesis before injecting 20 mg triamcinolone hexacetonide
Study: 2995755
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy under hyperbaric oxygenation (HBO)
Study: 22019031
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of low dose chemoprophylaxis
Study: 24461900
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg daily for 4 weeks
Study: 1692612
Drug: Bovine surfactant
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bovine surfactant therapy
Study: 57131
Drug: Injections of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections of antigen D in alginate
Study: 29627897
Drug: Cefiderocol 2
Normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cefiderocol 2 g every 8 h with 3-h infusion (3, 6, and 9 doses with furosemide, metformin, and rosuvastatin respectively)
Study: 24659610
Drug: Dietary supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplements (10 supplements daily including 100 mg resveratrol, 800 mg each of green, black, and white tea extract, 250 mg pomegranate extract, 650 mg quercetin, 500 mg acetyl-l-carnitine, 600 mg lipoic acid, 900 mg curcumin, 1 g sesamin, 1.7 g cinnamon bark extract, and 1.0 g fish oil)
Study: 24659610
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily multivitamin/mineral supplement)
Study: 22551128
Drug: Low-dose radioiodine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radioiodine (1.1 GBq [30 mCi])
Study: 22551128
Drug: High-dose radioiodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radioiodine (3.7 GBq [100 mCi])
Study: 10566623
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone withdrawal
Study: 22551128
Drug: Low-dose radioiodine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radioiodine plus thyrotropin alfa
Study: 22551128
Drug: High-dose radioiodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radioiodine plus thyroid hormone withdrawal
Study: 22551128
Drug: High-dose radioiodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radioiodine plus thyrotropin alfa
Study: 18386209
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatments; specific treatments not detailed in the abstract.
Study: 15970422
Drug: Self-administered breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered breathing exercises (intermediary outcome parameter).
Study: 12947065
Drug: BAY 12‐9566
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 12‐9566 800 mg orally bid continuously
Study: 12947065
Drug: gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine 1,000 mg/m2 intravenously on specified days
Study: 10817010
Drug: Continuous hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous hormone replacement therapy alone (Group A)
Study: 10817010
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of a half dose hormone replacement therapy and anxiolytic drug (Group B)
Study: 1508382
Drug: Calcium folinate
Normalized name: Calcium folinate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Calcium folinate (Citofolin Bracco S.p.A.) 15 mg/day per os starting from the 12th or 20th week of gestation
Study: 29446069
Drug: ACT-541468 (5-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-541468 (5-200 mg single oral dose)
Study: 29446069
Drug: ACT-541468 (≥25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-541468 (≥25 mg)
Study: 17917556
Drug: Venlafaxine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (mean dose 165 mg/day, SD=73.8; range 75-300 mg)
Study: 17917556
Drug: Paroxetine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (mean dose 26 mg/day, SD=15.04; range 10-60 mg)
Study: 19610037
Drug: Herbal preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal preparations
Study: 7480525
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment (four different compounds)
Study: 2265308
Drug: herbal yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: herbal yeast food supplement
Study: 299462
Drug: Prostaglandin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin (20 mg) and hypertonic saline (NaCl 5 and 10 g) with oxytocin
Study: 27299887
Drug: DCS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCS therapy (docetaxel at 40 mg/m2, cisplatin at 60 mg/m2 on day 1, S-1 at 40 mg/m2 twice daily for 2 weeks) followed by gastrectomy with D2 plus para-aortic nodal dissection
Study: 25958716
Drug: Oral chelated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chelated zinc with standard treatment (oral prednisolone)
Study: 25958716
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (oral prednisolone) alone
Study: 23637065
Drug: Cocoa with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa with skimmed milk intervention (40 g/day of cocoa powder with 500 mL skimmed milk)
Study: 23637065
Drug: Skimmed milk
Normalized name: Calcium fortified skimmed milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skimmed milk intervention (500 mL/day of skimmed milk)
Study: 21068698
Drug: Thrombomodulin alfa
Normalized name: Thrombomodulin Alfa
DrugBank: Thrombomodulin Alfa (DB05777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombomodulin alfa (TM‐α) 0.06 mg·kg for 30 min once daily for 6 days
Study: 21068698
Drug: Heparin 8
Normalized name: Heparine
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin 8 U·kg·h for 24 h for 6 days
Study: 17061634
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose hydrocortisone supplementation (Group C)
Study: 15557490
Drug: Interferon beta-1b
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1b (IFNB-1b) at a dosage of 8 MIU (250 mcg)
Study: 9706832
Drug: 6-week lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-week lisinopril treatment
Study: 30801373
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (observational cohort)
Study: 30801373
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (observational cohort)
Study: 30801373
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (overall responder analysis)
Study: 30170285
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) infusion (0.5 μg/kg per min for 4 hours)
Study: 11677003
Drug: Gabapentin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1200 mg)
Study: 26313650
Drug: Δ9‐THC (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Δ9‐THC (5 mg)
Study: 26313650
Drug: Δ9‐THC (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Δ9‐THC (15 mg)
Study: 26313650
Drug: Δ9‐THC (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Δ9‐THC (30 mg)
Study: 22785500
Drug: 0.10 mg
Normalized name: povidone-iodine 0.10 mg in 1 mL TOPICAL SOLUTION [Povidone Iodine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10 mg nor-β-CFT
Study: 22785500
Drug: 0.20 mg
Normalized name: FENTANYL 10.20 mg in 1 [USP'U] TRANSDERMAL PATCH [Fentanyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.20 mg nor-β-CFT
Study: 22785500
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg nor-β-CFT
Study: 22785500
Drug: 0.30 mg
Normalized name: Corona Multi-Purpose 0.30 MG/MG Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30 mg nor-β-CFT
Study: 22785500
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.10 mg nor-β-CFT)
Study: 20124183
Drug: Pertuzumab 420
Normalized name: pertuzumab 420 MG in 14 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertuzumab 420 mg (arm A)
Study: 20124183
Drug: Pertuzumab 1,050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertuzumab 1,050 mg (arm B)
Study: 8450517
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4.55 g/day of EPA and DHA)
Study: 8450517
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg twice daily) added to fish oil
Study: 8450517
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg twice daily) added to placebo
Study: 2429687
Drug: Citanest with
Normalized name: Citanest
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citanest with Octapressin (prilocaine 3% with 0.03 i.u./ml. of felypressin)
Study: 3356203
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of subcutaneous histamine and oral H2-antihistaminics (ranitidine or cimetidine)
Study: 28593326
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (0.5 µg/kg/h) during surgery and up to 2 hours in the recovery room
Study: 21697589
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (intense occupational therapy or non-specific interactive games)
Study: 19097714
Drug: Tibolone (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (1.25 mg/d)
Study: 15232803
Drug: Remifentanil, 5
Normalized name: Remifentanil, 50 mcg/mL-NaCl 0.9% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil, 5 microg/kg with glycopyrrolate, 0.2 mg
Study: 15232803
Drug: Fentanyl, 20
Normalized name: FentaNYL, 200 mcg buccal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl, 20 microg/kg with glycopyrrolate, 0.2 mg
Study: 11520836
Drug: Single infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single infusion of 5 mg/kg liposomal amphotericin B (n=46)
Study: 11520836
Drug: Daily infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily infusions of 1 mg/kg liposomal amphotericin B for five days (n=45)
Study: 3446803
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 mg oral dose)
Study: 30021457
Drug: ASAP intervention
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASAP intervention program plus treatment as usual
Study: 26290106
Drug: Intravenous 2
Normalized name: Premarin Intravenous 25 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 2 μg·kg(‐1)·min(‐1) dopamine
Study: 23331565
Drug: Sublingual allergen-specific
Normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual allergen-specific immunotherapy (SLIT) with Staloral 300R, Stallergenes, France
Study: 16987170
Drug: Riluzole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (100 mg b.i.d.)
Study: 11475269
Drug: Repaglinide 1
Normalized name: repaglinide 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide 1 mg
Study: 11475269
Drug: Repaglinide 4
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide 4 mg
Study: 9186283
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU; 120 mg/d orally for 2 months)
Study: 1488998
Drug: Subcutaneous rHuEPO
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rHuEPO (150 U/kg/week in three divided doses)
Study: 1488998
Drug: Intravenous rHuEPO
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rHuEPO (150 U/kg/week in three divided doses)
Study: 1488998
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (subcutaneous and intravenous)
Study: 27870694
Drug: Intrasession concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrasession concurrent aerobic before strength training (GAS: n = 39)
Study: 27870694
Drug: Intrasession concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrasession concurrent aerobic after strength training (GSA: n = 45)
Study: 24468428
Drug: Fenbendazole treatment
Normalized name: Fenbendazole
DrugBank: Fenbendazole (DB11410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenbendazole treatment group (623 cows)
Study: 15305160
Drug: Temozolomide as
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide as single agent
Study: 15305160
Drug: Temozolomide-based chemotherapy
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide-based chemotherapy (all groups)
Study: 11641669
Drug: Oxytocin administration
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin administration before placental delivery
Study: 11641669
Drug: Oxytocin administration
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin administration after placental delivery
Study: 9852693
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of mexiletine 2 mg.kg‐1
Study: 9852693
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of mexiletine 1 mg.kg‐1 with continuous administration of 1 mg.kg‐1.hr‐1 for 75 minutes
Study: 9852693
Drug: No mexiletine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No mexiletine administration
Study: 28099357
Drug: bilayered negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: bilayered negative pressure wound therapy (b‐NPWT) applied to thigh incision for 5 days
Study: 26581899
Drug: Fatigue, Age,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fatigue, Age, Fat Mass, Cancer Treatment Status
Study: 24152215
Drug: Control (sham-treatment)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (sham-treatment) group with inert neck device for 1 week
Study: 22265220
Drug: Intraperitoneal irrigation
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal irrigation with a solution of 240 mg gentamicin and 600 mg clindamycin
Study: 17402993
Drug: pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegylated interferon alpha2a (40 kDa) 180 microg/week plus ribavirin 1000/1200 mg/day for 48 weeks
Study: 15806621
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen 1
Study: 15806621
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen 2
Study: 15806621
Drug: Multi-stage chemotherapy
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-stage chemotherapy
Study: 12096303
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using photosensitizers activated by light
Study: 12096303
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PDT with other established modalities
Study: 12096303
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of photosensitizers for endoscopic diagnosis and treatment guidance
Study: 9802531
Drug: Alcohol (0.56
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.56 g/kg)
Study: 9593798
Drug: Capsaicin cream
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin Cream]
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin cream (1.5 g, 1%) applied for 15 min
Study: 9593798
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied for 15 min
Study: 29660005
Drug: Cabozantinib 100
Normalized name: cabozantinib 100 MG Daily Dose Carton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 100 mg/day